Clinical Trial

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
Protocol Amendment History 5 changes
notable Trial sites expanded: 27 -> 35 locations 2026-08-01
notable Trial sites expanded: 24 -> 27 locations 2026-06-17
notable Trial sites expanded: 17 -> 24 locations 2026-04-23
notable Primary completion pushed: 2027-09-30 -> 2030-02-28 2026-04-23
minor Completion pushed: 2027-12 -> 2030-08-30 2026-04-23
Trial Details
NCT Number NCT06990269
Lead Sponsor ADARx Pharmaceuticals, Inc.
Conditions Geographic Atrophy Secondary to Age-related Macular Degeneration
Enrollment 240 participants
Start Date 2025-11-10
Primary Completion 2030-02-28 (estimated)
Study Completion 2030-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-31